118 related articles for article (PubMed ID: 14692518)
1. ALK a novel lymphoma-associated tumor antigen for vaccination strategies.
Passoni L; Gambacorti-Passerini C
Leuk Lymphoma; 2003 Oct; 44(10):1675-81. PubMed ID: 14692518
[TBL] [Abstract][Full Text] [Related]
2. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.
Passoni L; Scardino A; Bertazzoli C; Gallo B; Coluccia AM; Lemonnier FA; Kosmatopoulos K; Gambacorti-Passerini C
Blood; 2002 Mar; 99(6):2100-6. PubMed ID: 11877285
[TBL] [Abstract][Full Text] [Related]
3. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas.
Passoni L; Gallo B; Biganzoli E; Stefanoni R; Massimino M; Di Nicola M; Gianni AM; Gambacorti-Passerini C
Haematologica; 2006 Jan; 91(1):48-55. PubMed ID: 16434370
[TBL] [Abstract][Full Text] [Related]
4. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
Chiarle R; Martinengo C; Mastini C; Ambrogio C; D'Escamard V; Forni G; Inghirami G
Nat Med; 2008 Jun; 14(6):676-80. PubMed ID: 18469826
[TBL] [Abstract][Full Text] [Related]
5. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.
Ait-Tahar K; Damm-Welk C; Burkhardt B; Zimmermann M; Klapper W; Reiter A; Pulford K; Woessmann W
Blood; 2010 Apr; 115(16):3314-9. PubMed ID: 20185586
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools.
Merkel O; Hamacher F; Sifft E; Kenner L; Greil R;
Mol Cancer Ther; 2011 Jul; 10(7):1127-36. PubMed ID: 21712478
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase proteins and malignancy.
Pulford K; Morris SW; Mason DY
Curr Opin Hematol; 2001 Jul; 8(4):231-6. PubMed ID: 11561161
[TBL] [Abstract][Full Text] [Related]
8. Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.
K Singh V; Werner S; Hackstein H; Lennerz V; Reiter A; Wölfel T; Damm-Welk C; Woessmann W
Clin Exp Immunol; 2016 Oct; 186(1):96-105. PubMed ID: 27414060
[TBL] [Abstract][Full Text] [Related]
9. B and CTL responses to the ALK protein in patients with ALK-positive ALCL.
Ait-Tahar K; Cerundolo V; Banham AH; Hatton C; Blanchard T; Kusec R; Becker M; Smith GL; Pulford K
Int J Cancer; 2006 Feb; 118(3):688-95. PubMed ID: 16114011
[TBL] [Abstract][Full Text] [Related]
10. The t(2;5) in human lymphomas.
Kadin ME; Morris SW
Leuk Lymphoma; 1998 Apr; 29(3-4):249-56. PubMed ID: 9684923
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.
Coluccia AM; Gunby RH; Tartari CJ; Scapozza L; Gambacorti-Passerini C; Passoni L
Expert Opin Ther Targets; 2005 Jun; 9(3):515-32. PubMed ID: 15948671
[TBL] [Abstract][Full Text] [Related]
12. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma.
Kutok JL; Aster JC
J Clin Oncol; 2002 Sep; 20(17):3691-702. PubMed ID: 12202671
[TBL] [Abstract][Full Text] [Related]
13. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
Eckerle S; Brune V; Döring C; Tiacci E; Bohle V; Sundström C; Kodet R; Paulli M; Falini B; Klapper W; Chaubert AB; Willenbrock K; Metzler D; Bräuninger A; Küppers R; Hansmann ML
Leukemia; 2009 Nov; 23(11):2129-38. PubMed ID: 19657361
[TBL] [Abstract][Full Text] [Related]
15. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
Cools J; Wlodarska I; Somers R; Mentens N; Pedeutour F; Maes B; De Wolf-Peeters C; Pauwels P; Hagemeijer A; Marynen P
Genes Chromosomes Cancer; 2002 Aug; 34(4):354-62. PubMed ID: 12112524
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
18. Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma.
Knörr F; Weber S; Singh VK; Pulford K; Reiter A; Woessmann W; Damm-Welk C
Clin Immunol; 2018 Oct; 195():77-81. PubMed ID: 30077013
[TBL] [Abstract][Full Text] [Related]
19. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
Mehrotra M; Medeiros LJ; Luthra R; Sargent RL; Yao H; Barkoh BA; Singh R; Patel KP
Hum Pathol; 2014 Oct; 45(10):1995-2005. PubMed ID: 25128227
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].
Shi Y; Chen G; Zhou XG; Gong LP; Yu R; Zheng YY; Xie JL; Jin Y
Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):235-9. PubMed ID: 20654121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
